Colorectal carcinoma (CRC) · line 1 · FOLFOX (mFOLFOX6)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-FOLFOX`

ID	`IND-CRC-ADJUVANT-STAGE3-FOLFOX`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-CRC`
Sources	`SRC-ESMO-COLON-2024` `SRC-NCCN-COLON-2025`

Notes

Standard stage III adjuvant. Decision on duration (3 vs 6 mo) per IDEA risk grouping.

Used By

Algorithms

ALGO-CRC-ADJUVANT - ALGO-CRC-ADJUVANT